The protein tyrosine kinase, fyn, in Alzheimer's disease pathology
- PMID: 8388744
- DOI: 10.1097/00001756-199304000-00024
The protein tyrosine kinase, fyn, in Alzheimer's disease pathology
Abstract
Immunohistochemistry was used to assess the distribution of protein tyrosine kinases in Alzheimer's disease (AD) pathology. One of these, fyn, exhibited an interesting pattern of immunoreactivity. Low levels of immunoreactivity were apparent in neurons from both normal and AD brain. However a subset of neurons in AD brain exhibited intense fyn immunoreactivity. Double label immunohistochemistry revealed that fyn-positive neurons were also positive for abnormally phosphorylated microtubule-associated protein, tau. Proline-directed kinases, whose activity is regulated by phosphorylation on tyrosine, may be responsible for abnormal tau phosphorylation. These results identify fyn as a candidate kinase for regulating putative proline-directed kinases involved in abnormal tau phosphorylation.
Similar articles
-
Phosphorylation of tau by fyn: implications for Alzheimer's disease.J Neurosci. 2004 Mar 3;24(9):2304-12. doi: 10.1523/JNEUROSCI.4162-03.2004. J Neurosci. 2004. PMID: 14999081 Free PMC article.
-
Critical residues involved in tau binding to fyn: implications for tau phosphorylation in Alzheimer's disease.Acta Neuropathol Commun. 2016 May 18;4(1):49. doi: 10.1186/s40478-016-0317-4. Acta Neuropathol Commun. 2016. PMID: 27193083 Free PMC article.
-
Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies.J Neural Transm (Vienna). 2001;108(12):1397-415. doi: 10.1007/s007020100016. J Neural Transm (Vienna). 2001. PMID: 11810404
-
Fyn, a potential target for Alzheimer's disease.J Alzheimers Dis. 2011;27(2):243-52. doi: 10.3233/JAD-2011-110353. J Alzheimers Dis. 2011. PMID: 21799250 Review.
-
Physiology and pathology of tau protein kinases in relation to Alzheimer's disease.J Biochem. 1997 Feb;121(2):179-88. J Biochem. 1997. PMID: 9089387 Review.
Cited by
-
Development of small-molecule Tau-SH3 interaction inhibitors that prevent amyloid-β toxicity and network hyperexcitability.Neurotherapeutics. 2024 Jan;21(1):e00291. doi: 10.1016/j.neurot.2023.10.001. Epub 2023 Dec 19. Neurotherapeutics. 2024. PMID: 38241154 Free PMC article.
-
Targeting Fyn Kinase in Alzheimer's Disease.Biol Psychiatry. 2018 Feb 15;83(4):369-376. doi: 10.1016/j.biopsych.2017.06.004. Epub 2017 Jun 13. Biol Psychiatry. 2018. PMID: 28709498 Free PMC article. Review.
-
Synapses and dendritic spines as pathogenic targets in Alzheimer's disease.Neural Plast. 2012;2012:247150. doi: 10.1155/2012/247150. Epub 2012 Feb 6. Neural Plast. 2012. PMID: 22474602 Free PMC article. Review.
-
Fyn kinase inhibition as a novel therapy for Alzheimer's disease.Alzheimers Res Ther. 2014 Feb 5;6(1):8. doi: 10.1186/alzrt238. eCollection 2014. Alzheimers Res Ther. 2014. PMID: 24495408 Free PMC article. Review.
-
Tau Proteins and Tauopathies in Alzheimer's Disease.Cell Mol Neurobiol. 2018 Jul;38(5):965-980. doi: 10.1007/s10571-017-0574-1. Epub 2018 Jan 3. Cell Mol Neurobiol. 2018. PMID: 29299792 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous